Abbott's Hytrin HYCAT results show reduction in BPH treatment failures, cost effectiveness -- AUA meeting.

ABBOTT's HYTRIN HYCAT STUDY REDUCES BPH TREATMENT FAILURES to 12.1% in patients with moderately severe symptoms compared to 24% for placebo-treated patients over a one-year period, according to results of the 2,084-patient trial presented April 24 at the American Urological Association annual meeting in Las Vegas. The randomized double-blind placebo-controlled Hytrin Community Assessment Trial conducted in 15 universities and 143 community-based sites collected data on efficacy of the alpha-1 blocker therapy in patients with benign prostatic hyperplasia over a one year period.